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Abstract
Background: Hemodialysis patient are at high risk for hepatitis B virus (HBV) infection.
Although preventive vaccination is done routinely, the response to vaccination is low in this patient
population. The aim of this study was to evaluate the effect of Levamizol, an enhancer of the
immune responsiveness, on different routs of vaccination, i.e., intradermal (ID) versus
intramuscular (IM), in stable chronic hemodialysis patients.
Materials and methods: Forty four chronic heamodialyses patient were divided into four equal
groups. The first group was received 40 μg HB vaccine intramuscularly. The second group was
received 20 μg HB vaccine intradermally. The third and the fourth group received 20 μg vaccine
IM or ID, respectively, in three doses plus oral Levamisole (100 mg for 12 day). After one and six
months from the last dose of vaccine, HBs antibody titers were measured.
Results: The response rate to vaccine (HBs Antibody>10 μg/L) in the routine IM HB vaccination
was low (60%). It increased to 70% with ID route. Levamisole significantly raised the response rate
to 90% (P < 0.01). Also in the Levamisole groups protective HB antibody titers were maintained
until the end of six months.
We conclude that HD patients must be vaccinated by ID route and addition of Levamisole. 
Levamisole also increases antibody maintenance.
Background
Hepatitis B virus (HBV) infection is a worldwide health
problem with increased incidence in developing countries
[1-4].
Despite improvements in infection control guidelines and
dialysis techniques, patients with chronic renal failure
(CRF) are at increased risk for HBV infection because of
their suppressed immunity and frequent exposure to
blood products [5-8]. Therefore, it is suggested that all
CRF patients be vaccinated against HBV [9-13]. With the
routine use of hepatitis B vaccination the incidence of
hepatitis B infection has been reduced significantly from
30% in 1976 to 0.05% in 1997 among patients on chronic
dialysis [13-15].
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The increased susceptibility to infections among these
patients is due to immunodeficiency status manifested by
abnormal phagocytosis, T and B-lymphocyte abnormali-
ties, and impaired responses to T cell dependent patho-
gens such as hepatitis B virus. Therefore, these patients are
predisposed to develop chronic hepatitis infections [16-
19].
Although preventive vaccination is done routinely in
patients with end stage renal failure (ESRF), antibody
response to vaccination is suppressed and its level rapidly
declines among patients on chronic dialysis due to the
decreased immunological response [15-17].
Levamisole is an anti helminthic drug which has a prop-
erty to stimulate T cell activity and enhance B lymphocyte
function. Thus, it can be used for up-regulation of defec-
tive immune function in patients with CRF [7]. Vaccina-
tion via the intradermal route (ID) is considered an
alternative method of vaccination which could be more
effective than the conventional intramuscular (IM) rout. It
is effective in inducing HBs antibody production by
increasing T and B lymphocyte responsiveness, probably
through facilitating a greater contact with the antigen
overtime [20-22].
Recent studies have shown that ID administered HB vac-
cine is an effective rout to induce anti-HBs Ag serum anti-
bodies. Furthermore, the ID administration of HB vaccine
has higher clinical efficacy to induce humoral immune
responses than the conventional IM route [23]. The aim of
this study was to investigate the effectiveness of Levamizol
in enhancing the immune response to different routs of
vaccination in hemodialysis patients, as well as the effect
on maintenance of the protective HBs antibody titer.
Patients and method
In our hemodialysis center from March 2002 to February
2003, 128 stable patients end stage renal disease were dia-
lyzed 3 times per week by low flux cellulosynthetic mem-
brane. After excluding of the patients with history of HB
vaccination, current therapy with any immunosuppres-
sive drugs, malnutrition, recent hospitalization (during
the last 3 months), and positive HBs antibody and/or Hbs
antigen, 44 stable chronic hemodialysis patients recruited
to the study (Table 1). None of the patients had significant
co-morbid conditions such as congestive heart failure,
uncontrolled diabetes mellitus or liver cirrhosis.
After obtaining of informed consent, 20 or 40 microgram
of recombinant human HB vaccine (from Heber Biotec,
S.A., Havana, Cuba, brochure no. 1-8-0090-LI) was
received to the patients three times; at the months 0, 1 and
6.
Each ml of the vaccine contained 20 microgram of surface
antigen protein (with >95% purity).
The patients randomly divided in to four groups (Table
1):
1-Group A: 11 patients received 2 ml (40 μg) of the vac-
cine, which was administered as a single intramuscular
injection in the deltoid muscle.
2- Group B: 11 patients received 1 ml (20 μg) of the vac-
cine intradermally in the ventral surface of the forearm.
3- Group C: 11 patients received 1 ml (20 μg) of HB vac-
cine intramuscularly, plus 100 mg Levamisole per day for
duration of 12 days, from 6 days before of vaccination
until 6 days after each vaccination.
4- Group D: 11 patients received 1 ml (20 μg) of the vac-
cine intradermally, plus 100 mg Levamisole per day for 12
day, from 6 days before of vaccination until 6 days after
each vaccination.
Demographic characteristics and the etiology of renal fail-
ure distributed uniformly in the four groups (Tabale-1).
Table 1: Demographic characteristics of the patients in the four groups
Age (years) Gender (male/female) Underlying disease (cases) p
Group A 47 ± 9.6 7/4 DM:(3), GN:(2), HTN:(2), 
UN:(3), O:(1)
ns.
Group B 45 ± 9.1 6/5 DM:(3), GN:(2), HTN:(2), 
UN:(3), O:(1)
ns.
Group C 48 ± 8.3 6/5 DM:(3), GN:(2), HTN:(2), 
UN:(3), O:(1)
ns.
Group D 41 ± 7.2 6/5 DM:(3), GN:(2), HTN:(2), 
UN:(3), O:(1)
ns.
It is non significant (ns) differences of age, gender and causes of renal failure in the four groups; DM: Diabetes Mellitus, GN: Glomerulonephritis, 
HTN: Hypertension, UN: Unknown causes, O: Other causes (includes: Alport syndrome in 1 case, Autosomal dominant polycystic disease in 1 
case, Nephrolithiasis in 1 case and obstructive uropathy in 1 case).Journal of Immune Based Therapies and Vaccines 2006, 4:3 http://www.jibtherapies.com/content/4/1/3
Page 3 of 5
(page number not for citation purposes)
One and six months after the last dose of vaccination pro-
tocol HBs antibody titers were measured by ELISA method
(DiaPlus Inc., Lot:8-112904, Italy).
HBs antibody titer more than10 IU was considered posi-
tive and the titer more than 100 IU was considered good
responders to vaccination protocol [24,25].
The antibody responses in the 4 groups were compared by
using X2 and Mann-Withney U test in Statistical Package
of Social Science (SPSS) version 12 (licensed to university
of Greenwich at 2003). P < 0.05 was considered signifi-
cant.
Results
In the 44 stable patients male to female ratio was 25 to 19
with the mean ( ± SD) age of 45 ± 8.6 years. Three of the
44 subjects were excluded due to death (1 case in group A)
or renal transplantation (2 cases; one case in group B and
the other in group C) during the study period.
HB antibody titer in the group A was significantly lower
than group B (28.9 ± 7 IU/L vs. 121.1 ± 82.3 IU/L, p =
0.04). Although the percent of seroconversion rate was
lower in the group A than the group B (60% vs. 70%), it
was not significant statistically. The antibody titers in
groups C and D (IM and ID routs with using of Levami-
sole) were 541.1 ± 494.4 IU/L and 297.2 ± 9 IU/L (p =
0.6), respectively. The seroconversion rate, also, was simi-
lar in the both groups (90%) (Table 2). Thus, addition of
Levamizol to intramuscular and intradermal vaccinations
increased the antibody titers, 514.2 IU/L (p = 0.001) and
176.1 IU/L (p = 0.01), respectively. Evaluation of anti-
body titers 6 months after the last dose of vaccination
showed that antibody concentration declined in all of the
four groups, but this decrement was attenuated in the C
group (IM+ Levamisole) and D group (ID+ Levamisole).
Antibody titers in the A, B and C groups approximately
were halved at the end of six months but it decreased only
30% in the D group.
Aside of the higher HB antibody titer in the C and D
groups, percentage of patients who retained HB antibody
titer as protective level was higher after six months of fol-
low up; i.e. protective antibody level persisted in 80% of
patients in the latter two groups, vs. 60% of patients in the
B group and only in 20% of patients in the A group (Table
2).
Although mild localized pruritus or pain was explained by
all of the patients in the B and D groups due to one ml of
intradermal vaccination, any major side effect was not
reported. Only one patient found mild generalized pruri-
tus and another patient reported mild abdominal pain
during the first week of Levamisole consumption,
although both of the symptoms were relived by continu-
ing of the drug and did not relapse at the succeeding
courses of Levamisole in.
Discussion
In our hemodialysis patients, antibody response (anti-
body titer more than 10 IU/L) to routine IM vaccination
of hepatitis B was low (60%) after one month, but it
increased to 70% with ID route. The response rate to both
IM and ID routs of vaccination increased significantly up
to 90% at the end of one month with presence of Levam-
isole. Addition of Levamisole could extend the protective
level of HB antibody titer and also the percentage of
responders at least until six months. By adding of Levam-
isole 80% of the patients found sustained protective anti-
body level after six months. Although the antibody titer
secondary to vaccination in C group (IM rout vaccination
plus Levamisole) was higher than D group (ID rout vacci-
nation plus Levamisole) at this time, the difference did
not reach significant statistically.
Table 2: Hepatitis B antibody titers based on the rout of vaccination
HB vaccine groups positive seroconversion rate after 1 month 
(antibody titer/IU)
positive seroconversion rate after 6 months 
(antibody titer/IU)
Group A (intra-muscular route by 40 
microgram vaccine alone)
60% (28.9 ± 7) *P = 0.04 20% (16.7 ± 4)
Group B (intra-dermal route by 20 microgram 
vaccine alone)
70% (121.1 ± 82.3) #p = 0.005 60% (58 ± 7)
Group C (intra-muscular route by 20 
microgram vaccine plus Levamisole)
90% (543.1 ± 494.4) §p = 0.008 80% (304 ± 7)
Group D (intra-dermal route by 20 microgram 
vaccine plus Levamisole)
90% (297.2 ± 90) €p = 0.6 80% (209 ± 46)
Seroconversion rate percent (when Ab titer was more than10 IU/L) and HB antibody titers (IU/L) one month and six months after different routs 
of vaccination. *Denotes comparison of antibody titer between groups A and B.
# Denotes comparison of antibody titer between groups B and D.
§Denotes comparison of antibody titer between groups A and C.
€ Denotes comparison of antibody titer between groups C and D.Journal of Immune Based Therapies and Vaccines 2006, 4:3 http://www.jibtherapies.com/content/4/1/3
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We suggest that hemodialysis patients vaccinated via the
ID route would be better respond than the conventional
IM rout, which also suggested by Theresa in 1998 [6],
Pyone Keyi in 2002 [21] and Rangle in 2000 [4].
Addition of Levamisole to vaccination protocol would
further enhance the immunological response. The differ-
ence between the two routes of injection and with or with-
out taking of Levamisole supplement reached highly
statistical significance (Table 2).
Our results further confirms the report of Ayli et al [7],
which showed that Levamisole increases both serum anti-
body conversion rate and the duration that the antibody
titer is maintained. Kayatas [26] in another study reported
the effect of Levamisole on the percentage of patients who
found HB Antibody seroconversion but they did not
explain the amount of antibody titers in detail. In our
study only non-vaccinated stable hemodialysis patients
were received Levamisole via ID or IM routs, but in the
Kayatas study response rate of the pre-vaccinated patients
via conventional rout was examined. The higher antibody
response after ID vaccination could be due to more effec-
tor immune cells accessible in derm composed of Langer-
hans and dendritic cells [27]. The difference of
immunomodulatory response to vaccination routs would
be disappeared when Levamisole is added to the vaccina-
tion protocol.
Quadruple injection protocol and addition of booster
doses of vaccine when is necessary was suggested by Vlas-
sopoulos DA etal. [28]. But it is not cost effective for devel-
oping countries, such as us. Each dose of vaccine is
approximately U.S.$ 3 but Levamisole has negligible price
with minimal side effects if it be used for a short period of
time such as 12 days as we used. The plasma elimination
half-life of Levamisole is between 3–4 hours. Levamisole
is extensively metabolized by the liver in humans and the
metabolites excreted mainly by the kidneys (70% over 3
days). The elimination half-life of metabolite excretion is
16 hours. Approximately 5% is excreted in the feces. Less
than 5% is excreted unchanged in the urine and less than
0.2% in the feces. The drug is not dialyzable, by hemo- or
peritoneal membranes [29].
The antibody production rate could be more stimulated
by triggering of T helper cells, such as Levamisole or other
immunomodulatory drugs. Levamisole can act either as
immunostimulant depending upon dose administered
the timing of its administration and host genetic back-
ground [30]. Levamisole also could induce an increase in
the level of interleukin 2 receptor [31] and T helper to T
suppressor ratio in many dermatologic disorders [32].
We conclude that hemodialysis patients should be vacci-
nated perfectly by ID or IM route in addition of Levami-
sole. Future studies with larger number of patients are
needed to validate our results as a routine protocol in
hemodialysis patients.
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